Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Latest from The Tisch Cancer Institute

Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.
Karyn Aalami Goodman, MD, MS, an internationally recognized expert on gastrointestinal cancers, has joined the Icahn School of Medicine at Mount Sinai as Associate Director for Clinical Research at The Tisch Cancer Institute. She is also Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology.
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).
William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.
Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.
William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.
Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis. 
Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.
Publication Bottom Border
Border Publication